	JC33
TRANSMIZTAL	ggs
FORM N	\ <u>`</u>
	C.

Application Serial Number 09/256,156

Filing Date February 24, 1999

First Named Inventor Gillies

Group Art Unit 1643

Examiner Name Not Yet Assigned

Attorney Docket No. LEX-003

ENCLOSUDES (check all that apply)							
ENCLOSURES (check all that apply) Fee Transmittal Form							
⊠ F	Fee Transmittal Form			ation (PTO-1553)		of Patent Appeals and Interferences	
	☐ Check Attached☐ Copy of FeeTransmittal Form		Formal Drawing	g(s)		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
	Amendment/Response		Petition Routing and Accompany Convert to a Pro Application			Status Letter	
	After Final				\boxtimes	Return Receipt Postcard	
	☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson		Power of Attorn (Revocation of			Certificate of First Class Mailing under 37 C.F.R. 1.8	
	including Drawings [Total Sheets]		Terminal Discla	aimer	\boxtimes	Additional Enclosure(s) (please identify below)	
	Extension of Time Request		Executed Decla Attorney for Ut Patent Applicat		Copy of Form PTO-1661 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg.)		
	Information Disclosure Statement Form PTO-1449		Small Entity Statement		SequenceListing (8 pgs.) Computer Readable Copy of Sequence Submission Statement Verifying Identity of Sequence Submission Copies (2 pgs.)		
	Copies of IDS Citations		Request for Refund		0.00.	moston Copies (2 pgs/)	
	Certified Copy of Priority Document(s)		After Allowance Communication to Group				
	Response to Missing Parts/ Incomplete Application	i					
COR	CORRESPONDENCE ADDRESS SIGNATURE BLOCK						
						Respectfully submitted,	
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100 waller4006/14.797978-1			Date: June 21, 1999 Reg. No. 41,418 Tel. No.: (617) 248 Fax No.: (617) 248	-7240	Patrick R.H. Waller, Ph.D. Agent for Applicant(s) Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110		

FEE TRANSMITTAL

Note: Effective October 1, 1997. Patent fees are subject to annual revision

Complete if Known				
Application Serial Number	09/256,156			
Filing Date	February 24, 1999			
First Named Inventor	Gillies			
Group Art Unit	1643			
Examiner Name	Not Yet Assigned			
Attorney Docket No.	LEX-003			

METHOD OF PAYMENT	FEE CALCULATION (continued)			
1. A Payment Enclosed:	3. ADDI	ΓΙΟΝAL FE	ES	
Check Money Order Other	Large	Small		
	Entity	Entity	En Danisiation En Daid	
2. The Commissioner is hereby authorized to credit JC3	Fee	Fee	Fee Description Fee Paid	
or charge any fee indicated below to Deposit Account	(4)	(\$)		
No. 20-0531.	130 130 130	65	Surcharge - late filing fee or oath	
Required Fees (copy of this theet enclosed)	E 30		· · · · · · · · · · · · · · · · · · ·	
Additional fee required under 37 CFR 116 and 1.17.	50	25	Surcharge - late provisional filing fee or	
1.17.	ž/ 120	130		
Overpayment Credit.	130		Non-English specification For filing a request for reexamination	
\ Jakor	2,520	2,520	For ining a request for reexamination	
FEE CALCULATION PATENTS	110	55	Extension for reply within first month \$110.00	
1. FILING FEE	380	190	Extension for reply within second	
I. FILING FEE	500	170	month	
Large Entity	870	435	Extension for reply within third month	
Fee (\$) Fee Description Fee Paid	1,360	680	Extension for reply within fourth	
200 (0)	Í		month	
	1,850	925	Extension for reply within fifth month	
760 Utility filing fee	300	150	Notice of Appeal	
. 310 Design filing fee	300	150	Filing a brief in support of an appeal	
150 Provisional filing fee	260	130	Request for oral hearing	
	130	130	Petitions to the Commissioner	
Number Number Rate Amount	50	50	Petitions related to provisional applications	
Number Number Rate Amount Filed Extra	240	240	Submission of Information Disclosure	
- Total Claims - 20 = x \$ 18.00 =	240	240	Statement (37 CFR 1.97(c))	
20 <u> </u>	130	130	Submission of Information Disclosure	
Independent			Statement (37 CFR 1.97(d))	
Claims $-3 = x \$ 78.00 =$	760	380	Filing a submission after final	
			rejection	
			(37 CFR 1.129(a))	
Multiple Dependent Claim(s), if any \$260.00 =	760	380	For each additional invention to be	
TOTAL.			examined (37 CFR 1.129(b))	
TOTAL: SMALL ENTITY DISCOUNT:			Other (Specify)	
SUBTOTAL (1) (\$)	1			
2. AMENDMENT CLAIM FEES	1			
Claims Highest No. Present Rate Fee Paid	1		SUBTOTAL (3) (\$) 110.00	
Remaining Previously Extra			(4)	
After Amend. Paid For				
Total - v. \$ 19.00 -	ļ		SUBTOTAL (1) 0.00	
Total - = x \$ 18.00 = Indep = x \$ 78.00 =			SUBTOTAL (1) 0.00 SUBTOTAL (2) 0.00	
First Presentation of Multiple Dep. + \$260.00 =	{		SUBTOTAL (3) 110.00	
Claim			(,	
TOTAL: (\$)				
SMALL ENTITY DISCOUNT: (\$)				
SUBTOTAL (2) (\$)	1		TOTAL \$ 110.00	
CORRESPONDENCE ADDRESS	SIGNATURE BLOCK			
Direct all correspondence to:	Respectfully submitted,			
Patent Administrator			0+	
Testa, Hurwitz & Thibeault, LLP	Date: June 2		Value KH WW	
High Street Tower	Reg. No.: 41		Patrick R.H. Waller, Ph.D.	
125 High Street	Tel. No.: (6			
Boston, MA 02110	Fax No.: (6	17) 248-710		
Tel. No.: (617) 248-7000			High Street Tower	
Fax No.: (617) 248-7100			125 High Street	
l ' '	1		Boston, MA 02110	



Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT	DATE	FIRST NAMED APPLICANT	ATTORNE	Y DOCKET NO./TITLE
09/256,156	02/24/99	GILLÍE	S	S	LEX-003
021323		024	2/0421		
TESTA HURWI	TZ & THIBEA	JLT	•	NOT A	SSIGNED
HIGH STREET	TOWER				
125 HIGH ST	REET	•			
BOSTON MA 0:	2110			1643	
•			DATE MA	ILED:	
		, ,			04/21/9

NOTICE TO FILE MISSING PARTS OF APPLICATION Filing Date Granted

An Application Number and Filing Date have been assigned to this application. The items indicated below, however, are missing. Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). If any of items 1 or 3 through 5 are indicated as missing, the SURCHARGE set forth in 37 CFR 1.16(e) of \$\subseteq\$ \$\frac{1}{2}\$\$ \$\frac{1}{2}\$\$ \$\frac{1}{2}\$\$, or \$\subseteq\$ \$\frac{1}{2}\$\$ \$\frac{1}{2}\$\$ \$\frac{1}{2}\$\$ \$\frac{1}{2}\$\$. On the subset of the subse

37 CFR 1:136(a). If any of items 1 or 3 through 5 are indicated as missing, the SURCHARGE set forth in 37 CFR 1.16(e) of □ \$65.00 for a small entity in compliance with 37 CFR 1.27, or □ \$130.00 for a non-small entity, must also be timely submitted in reply this NOTICE to avoid abandonment.							
If all required items on this form are filed within the period set above, the total amount owed by applicant as a \Box small entity (statement filed) \Box non-small entity is \Box \Box .							
1. The statutory basic filing fee is: missing. insufficient. Applicant must submit \$\frac{\sqrt{1}}{2}} \tag{0} \tag{0} \tag{0} to complete the basic filing fee and/or file a small entity statement}							
claiming such status (37 CFH 1.27). 2. The following additional claims fees are due:							
\$ 432.60 for 24 total claims over 20.							
\$ 78.00 forindependent claims over 3.							
\$\(\sum_{\color=0}^{\infty}\) for multiple dependent claim surcharge. Applicant must either submit the additional claim fees or cancel additional claims for which fees are due.							
3. The oath or declaration: is missing or unsigned.							
does not cover the newly submitted items.							
An oath or declaration in compliance with 37 CFR 1. 63, including residence information and identifying the application by							
the above Application Number and Filing Date is required. 4. The signature(s) to the oath or declaration is/are by a person other than inventor or person qualified under 37 CFR 1.42, 1.43 or 1.47.							
A property signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.							
□ 5. The signature of the following joint inventor(s) is missing from the oath or declaration:							
An oath or declaration in compliance with 37 CFR 1.63 listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date, is required.							
☐ 6. A \$50.00 processing fee is required since your check was returned without payment (37 CFR 1.21(m)).							
7. Your filing receipt was mailed in error because your check was returned without payment.							
8. The application was filed in a language other than English. Applicant must file a verified English translation of the application, the \$130.00 set forth in 37 CFR 1.17(k), unless previously submitted, and a statement that the translation is accurate (37 CFR 1.52(d)).							
□ 9. OTHER:							
Direct the reply and any questions about this notice to "Attention: Box Missing Parts."							

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202




UNITED STANDEPARTMENT OF COMMERCI Patent and Addemark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

FILING/RECEIPT DATE ATTORNEY DOCKET NO./TITLE FIRST NAMED APPLICANT APPLICATION NUMBER 9/256,156 GILLIES .021323 242/0421 NOT ASSIGNED TESTA HURWITZ & THIBEAU HIGH STREET TOWER 125 HIGH STREETS 建铁色 BOSTON MA 02110 04/21/99 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SECULENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s): 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). 7. OTHER APPLICANT MUST PROVIDE: N An initial or substitute computer readable form (CRF) copy of the "Sequence Listing." \An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT: For Rules Interpretation, call (703) 308-1123. For CRF submission help, call (703) 308-4212. For Patentin software help, call (703) 308-6856.

Customer Service Center

Initial Patent Examination Division (703) 308-1202



PATENT
Attorney Docket No. LEX-003
(4006/14)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Gillies et al.

SERIAL NO.:

09/256,156

GROUP NO.:

1643

FILING DATE:

February 24, 1999

EXAMINER:

Not Yet Assigned

TITLE:

Enhancing the Circulating Half Life of Antibody-Based Fusion Proteins

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this 21st day of June, 1999.

Rachel K. McLendon Kent

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

RECEIVED
JUN 29 1999.

Submitted herewith is/are:

TECH CENTER 1600/2900

Transmittal Form (1 pg.); Fee Transmittal Form (1 pg.); Petition for Extension of Time Under 37 CFR 1.136(a) (1 pg.); Copy of Form PTO-1661 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg.); Substitute Paper Copy of Sequence Listing (8 pgs.); Substitute Computer Readable Copy of Sequence Submission; Statement Verifying Identity of Sequence Submission Copies (2 pgs.); Return Mailroom Postcard; all mailed under a Certificate of First Class Mailing Under 37 C.F.R. 1.8 on June 21, 1999.

PATENT

Attorney Docket No. LEX-003

(4006/14)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et al.

JCვვ

SERIAL NÓ.:

09/256,156

GROUP NO.:

1643

FILING DATE:

February 24, 1999

EXAMINER:

Not Yet Assigned

TITLE: JUL BATENT & TRA

Enhancing the Circulating Half Life of Antibody-Based Fusion Proteins

Box SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. This replies to the Patent Office Letter dated April 21, 1999

e: If these papers are filed before the office letter issues adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

A copy of the Patent Office Letter is enclosed.

2. Submitted herewith is/are

(check each item as applicable)

- A. a substitute paper copy of the Sequence Listing for this application with each sequence assigned a separate identifier.
- **B.** a substitute copy, in computer readable form, of the Sequence Listing for this application.

Submission Of Paper Copy And/Or Computer Readable Copy Of Sequence Listing For Invention Containing Nucleotide And/Or Amino Acid Sequence Serial No.

Page 2 of 2

STATEMENT

3.	I hereby state that:						
	(complete applicable items A, B and/or C)						
	A.	herev	the content of the paper and computer readable copies submitted vith are the same.				
	В.		the content of the computer readable copy submitted herewith is the e as the Sequence Listing appearing on pages to of the original ification as filed.				
	C.	\boxtimes	this submission includes no new matter.				
				Respectfully submitted,			
Date	e June	21. 1	999	Patrior RH Wall			
Date: June 21, 1999 Reg. No. 41,418			Patrick R.H. Waller, Ph.D.				
J		,		Agent for Applicant(s)			
				Testa, Hurwitz, & Thibeault, LLP			
Tel. No.: (617) 248-7240			248-7240	High Street Tower			
Fax No.: (617) 248-7100			48-7100	125 High Street			
				Boston, Massachusetts 02110			

waller4006/14.797977-1